UT-MD Anderson Cancer Center: Biomarker-Directed Combination Effective in Immunotherapy-Resistant Lung Cancer
February 14, 2024
February 14, 2024
HOUSTON, Texas, Feb. 14 (TNSres) -- The University of Texas's MD Anderson Cancer Center issued the following news release:
* * *
Phase II trial finds durvalumab plus ceralasertib boosted immune response and improved outcomes in patients with lung cancer
* * *
A specific combination of targeted therapy and immunotherapy may better help patients with non-small cell lung cancer (NSCLC) overcome inherent immune resistance and reinvigorate anti-tumo . . .
* * *
Phase II trial finds durvalumab plus ceralasertib boosted immune response and improved outcomes in patients with lung cancer
* * *
A specific combination of targeted therapy and immunotherapy may better help patients with non-small cell lung cancer (NSCLC) overcome inherent immune resistance and reinvigorate anti-tumo . . .